Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.76 |
| ▸ | BCR | P11274 | 2/20 | 0.76 |
| ▸ | ABL2 | P42684 | 2/20 | 0.65 |
| ▸ | BRAF | P15056 | 5/20 | 0.64 |
| ▸ | EGFR | P00533 | 4/20 | 0.63 |
| ▸ | KIT | P10721 | 2/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | MLNR | O43193 | 1/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.62 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | CSF1R | P07333 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9610973 | 0.97 | ABL1 (0.76) | ABL1BCRABL2BRAFEGFR | |
| SCHEMBL10265557 | 0.97 | ABL1 (0.75) | ABL1BCRABL2BRAFEGFR | |
| SCHEMBL10265843 | 0.94 | ABL1 (0.75) | ABL1BCRABL2BRAFEGFR | |
| SCHEMBL10264998 | 0.94 | ABL1 (0.75) | ABL1BCRABL2BRAFEGFR | |
| SCHEMBL10265087 | 0.94 | ABL1 (0.75) | ABL1BCRABL2 | |
| SCHEMBL15499610 | 0.94 | ABL1 (0.67) | ABL1BCRABL2BRAFEGFR | |
| SCHEMBL10266444 | 0.93 | ABL1 (0.69) | ABL1BCRABL2BRAFEGFR | |
| SCHEMBL10265301 | 0.92 | ABL1 (0.76) | ABL1BCRABL2BRAFEGFR | |
| SCHEMBL9610989 | 0.92 | ABL1 (0.69) | ABL1BCRBRAFEGFRRET | |
| SCHEMBL10266185 | 0.92 | ABL1 (0.75) | ABL1BCRABL2BRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013101281-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | ARIAD PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2012139027-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| WO-2007075869-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885BCR 250/4885ABL2 1006/4885 |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885BCR 250/4885ABL2 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.